Scott A. Ezell, Ph.D. - Publications

2012 Biochemistry Sackler School of Graduate Biomedical Sciences (Tufts University) 

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. PMID 26824321 DOI: 10.18632/oncotarget.7036  0.76
2015 Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D'Cruz CM. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. Oncotarget. 6: 2407-20. PMID 25537515 DOI: 10.18632/oncotarget.2964  0.76
2014 Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, Byth KF. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget. 5: 4990-5001. PMID 24970801  0.76
2014 Kottakis F, Foltopoulou P, Sanidas I, Keller P, Wronski A, Dake BT, Ezell SA, Shen Z, Naber SP, Hinds PW, McNiel E, Kuperwasser C, Tsichlis PN. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. Cancer Research. 74: 3935-46. PMID 24853546 DOI: 10.1158/0008-5472.CAN-13-2733  0.76
2014 Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell SA, Doxaki C, Kampranis SC, Kottakis F, Tsichlis PN. The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection. Plos Pathogens. 10: e1004136. PMID 24830456 DOI: 10.1371/journal.ppat.1004136  0.76
2014 Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, Guo A, Xie J, Comb MJ, Iliopoulos D, Tsichlis PN. Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Molecular Cell. 53: 577-90. PMID 24462114 DOI: 10.1016/j.molcel.2013.12.018  0.76
2013 Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. Acs Chemical Biology. 8: 2145-50. PMID 23899692 DOI: 10.1021/cb400430t  0.76
2012 Ezell SA, Tsichlis PN. Akt1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the IFN response. Transcription. 3: 305-9. PMID 23117821 DOI: 10.4161/trns.21904  0.76
2012 Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T, Comb MJ, Sourvinos G, Tsichlis PN. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proceedings of the National Academy of Sciences of the United States of America. 109: E613-21. PMID 22315412 DOI: 10.1073/pnas.1115029109  0.76
Show low-probability matches.